- Home
- CNEY vs GOVX Comparison
CNEY vs GOVX Comparison
Compare CNEY & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNEY | GOVX |
|---|---|---|
| Founded | 2018 | 2001 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.3M | 12.2M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | CNEY | GOVX |
|---|---|---|
| Price | $0.60 | $0.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | ★ 1.9M | 547.9K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $36,049,275.00 | $3,353,560.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 8.52 |
| 52 Week Low | $0.64 | $0.37 |
| 52 Week High | $12.23 | $2.75 |
Technical Indicators
Market Signals| Indicator | CNEY | GOVX |
|---|---|---|
| Relative Strength Index (RSI) | 13.40 | 31.95 |
| Support Level | $0.71 | $0.37 |
| Resistance Level | $1.50 | $0.41 |
| Average True Range (ATR) | 0.11 | 0.03 |
| MACD | -0.04 | 0.00 |
| Stochastic Oscillator | 2.52 | 8.88 |
Price Performance
Historical ComparisonAbout CNEY CN Energy Group Inc.
CN Energy Group Inc along with its subsidiaries is a manufacturer and supplier of wood-based activated carbon that is used in pharmaceutical manufacturing, industrial manufacturing, water purification, environmental protection, and food and beverage production and a producer of biomass electricity generated in the process of producing activated carbon. The firm generates a majority of its revenue from Activated carbon.
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.